Based on these results, we hypothesized that hsa-miR-26a-5p can act synergistically with the PI3K inhibitor in metformin-resistant breast cancer cells, resulting in decreased migration and proliferation capacity. The gene discussed is PIK3CA; the disease is breast carcinoma.